

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

RECEIVED

Bring completed form to:
File Information Unit
Crystal Plaza Three, Room 1D01
2021 South Clark Place
Arlington, VA
Telephone: (703) 308-2733

MAR 10 2005
File Information Unit

In re Application of

Application Number
07/310252Filed
2/13/89Paper No. 1026

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____ line _____.

United States Patent Number 6180370, column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____.

Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:

For published applications that are still pending, a member of the public may obtain a copy of:


- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:


- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the file contents;
 - the pending application as originally filed; or
 - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the pending application as originally filed.



Signature



Typed or printed name



Date

FOR PTO USE ONLY

Approved by: 

File Information Unit

Unit: _____

Registration Number, if applicable



Telephone Number

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1D01, 2021 South Clark Place, Arlington, VA.



US006180370B1

(12) **United States Patent**
Queen et al.

(10) **Patent No.:** US 6,180,370 B1
(45) **Date of Patent:** *Jan. 30, 2001

(54) **HUMANIZED IMMUNOGLOBULINS AND METHODS OF MAKING THE SAME**

(75) Inventors: **Cary L. Queen**, Los Altos; **Harold E. Sellick**, Belmont, both of CA (US)

(73) Assignee: **Protein Design Labs, Inc.**, Fremont, CA (US)

(*) Notice: Under 35 U.S.C. 154(b), the term of this patent shall be extended for 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **08/484,537**

(22) Filed: **Jun. 7, 1995**

Related U.S. Application Data

(63) Continuation-in-part of application No. 07/634,278, filed on Dec. 19, 1990, now Pat. No. 5,530,101, which is a continuation-in-part of application No. 07/590,274, filed on Sep. 28, 1990, now abandoned, which is a continuation-in-part of application No. 07/310,252, filed on Feb. 13, 1989, now abandoned, which is a continuation-in-part of application No. 07/290,975, filed on Dec. 28, 1988, now abandoned.

(51) **Int. Cl.**⁷ **A61K 39/395**

(52) **U.S. Cl.** **435/69.6; 435/172.3; 435/328; 530/387.3; 530/388.2; 424/133.1; 424/143.1**

(58) **Field of Search** **424/133.1, 143.1; 435/328, 69.6, 172.3; 530/387.3, 388.2**

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,578,335	3/1986	Urdal et al.	530/351
4,816,397	3/1989	Boss et al.	.	
4,816,565	3/1989	Honjo et al.	435/69.1
4,816,567	3/1989	Cabilly et al.	.	
4,845,198	7/1989	Urdal et al.	530/387
4,867,973	9/1989	Goers et al.	.	
5,198,359	3/1993	Taniguchi et al.	.	
5,225,539	7/1993	Winter.	.	
5,530,101 *	6/1996	Queen et al.	.	
5,585,089 *	12/1996	Queen et al.	.	
5,693,761 *	12/1997	Queen et al.	.	
5,693,762 *	12/1997	Queen et al.	.	

FOREIGN PATENT DOCUMENTS

0 120 694	10/1984	(EP).
2-0120 694	10/1984	(EP).
1-0125 023	11/1984	(EP).
0171496	2/1986	(EP).
0173494	3/1986	(EP).
0184187	6/1986	(EP).
0256654	7/1987	(EP).
0239400	9/1987	(EP).
1-0239 400	9/1987	(EP).
2-0239 400	9/1987	(EP).
0266663	6/1988	(EP).
1 0318 554	6/1989	(EP).
0 323 806	7/1989	(EP).
1-0323 806	7/1989	(EP).
0 0328 404	8/1989	(EP).
0 365 209	4/1990	(EP).

2 0365 209	4/1990	(EP).
0 365 997	5/1990	(EP).
1-0368 684	5/1990	(EP).
2 0365 997	5/1990	(EP).
0 125 023	6/1991	(EP).
0456216	10/1991	(EP).
0460167	12/1991	(EP).
1-0519 596	12/1992	(EP).
1-0592 106	4/1994	(EP).
239400	8/1994	(EP).
2-0188 941	10/1987	(GB).
2188941	10/1987	(GB).
8928874	12/1989	(GB).
WO 86/05513	9/1986	(WO).
WO 87/02671	5/1987	(WO).
WO88/09344	12/1988	(WO).
WO 89/01783	3/1989	(WO).
WO89/09622	10/1989	(WO).
WO 90/07861	7/1990	(WO).
91/09967	7/1991	(WO).
WO 91/09966	7/1991	(WO).
WO 92/11018	7/1992	(WO).
WO 92/11383	7/1992	(WO).
WO92/11018	7/1992	(WO).
WO93/02191	2/1993	(WO).
WO 93006231	4/1993	(WO).
WO94/11509	5/1994	(WO).
WO 96/05229	2/1996	(WO).

OTHER PUBLICATIONS

George et al Current Methods in Sequence Comparison and Analysis in Macromolecular Sequencing and Synthesis, 127-148, 1988.*

Barton et al Protein Sequencing Alignment and Database Screening Protein Structure Prediction. 31-63, 1996.*

(List continued on next page.)

* cited by examiner

Primary Examiner—Julie Burke

(74) *Attorney, Agent, or Firm*—Townsend and Townsend and Crew LLP

ABSTRACT

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.